Gallic acid improves the metformin effects on diabetic kidney disease in mice. Issue 1 (31st December 2023)

• Record Type: Journal Article
• Authors: Hong, Yan; Wang, Jidong; Sun, Wenjuan; Zhang, Lai; Xu, Xuefang; Zhang, Kaiyue
• Is Part Of: Renal failure. Volume 45:Issue 1(2023)
• Publication Date: 2023-12-31
• Subjects: Gallic acid -- metformin -- diabetes mellitus -- nephropathy; Chronic renal failure -- Periodicals; Acute renal failure -- Periodicals; Uremia -- Periodicals; 616.614005
• DOI: 10.1080/0886022X.2023.2183726
• Languages: English
• ISSNs: 0886-022X

Abstract

Abstract: Objectives: Metformin is an antidiabetic agent that is used as the first-line treatment of type 2 diabetes mellitus. Gallic acid is a type of phenolic acid that has been shown to be a potential drug candidate to treat diabetic kidney disease, an important complication of diabetes. We aimed to test whether a combination of gallic acid and metformin can exert synergetic effect on diabetic kidney disease in diabetic mice model. Methods: Streptozotocin (65 mg/kg) intraperitoneal injection was used to induce diabetic kidney disease in mice. The diabetic mice were treated with saline (Vehicle), gallic acid (GA) (30 mg/kg), metformin (MET) (200 mg/kg), or the combination of gallic acid (30 mg/kg) and metformin (200 mg/kg) (GA + MET). Results: Our results demonstrated that compared to the untreated diabetic mice, all three strategies (GA, MET, and GA + MET) exhibited various effects on improving renal morphology and functions, reducing oxidative stress in kidney tissues, and restoring AMP-activated protein kinase (AMPK)/silent mating type information regulation 2 homolog 1 (SIRT1) signaling in kidney tissues of diabetic mice. Notably, the combination strategy (GA + MET) provided the most potent renal protection effects than any single strategies (GA or MET). Conclusion: Our results support the hypothesis that gallic acid might serve as a potential supplement to metformin to enhance the therapeutical effect of metformin.